We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Screens Newborns for Cytomegalovirus

By LabMedica International staff writers
Posted on 25 Jan 2012
A real-time polymerase-chain-reaction (rt-PCR)-based assay has been developed to test saliva specimen obtained at birth for Cytomegalovirus (CMV).

The standard assay for newborn CMV screening is rapid culture performed on saliva specimens, which cannot be automated, has been compared with rt-PCR assays performed on similar specimens. More...


Scientists at the University of Alabama (Birmingham, AL, USA) carried out a prospective, multicenter screening study of newborns comparing real-time PCR assays of liquid-saliva and dried-saliva specimens with rapid culture of saliva specimens obtained at birth. The infants were born at seven hospitals in the USA from June 2008 through November 2009.

A rapid-culture assay for the detection of early-antigen fluorescent foci, involving a monoclonal antibody against the major immediate early antigen of CMV, was used to detect CMV in saliva specimens. The rt-PCR protocol for dried-blood spots was performed to detect CMV DNA in saliva samples. A sample was considered positive if five or more copies per reaction were detected. The detection of CMV DNA was performed using the ABI 7500 Real-time PCR System (Applied Biosystems Inc, Foster City, CA, USA) and ABsolute QPCR Low ROX Mix (ABgene USA, Rockford, IL, USA).

A total of 177 of 34,989 infants were positive for CMV, according to at least one of the three methods. Of 17,662 newborns screened with the use of the liquid-saliva PCR assay, 17,569 were negative for CMV, and the remaining 85 infants had positive results on both culture and PCR assay. The sensitivity and specificity of the liquid-saliva PCR assay were 100% and 99.9%, respectively. Of 17,327 newborns screened by means of the dried-saliva PCR assay, 74 were positive for CMV, whereas 76 were found to be CMV-positive on rapid culture.

The authors conclude that saliva is a more reliable type of specimen than dried-blood spots for identifying congenital CMV infection by means of PCR assay and can be an effective tool for mass screening of newborns for CMV. Real-time PCR assays of both liquid-and dried-saliva specimens showed high sensitivity and specificity for detecting CMV infection and should be considered potential screening tools for CMV in newborns. The study was published online on June 2 2011, in the New England Journal of Medicine (NEJM).

Related Links:

University of Alabama
Applied Biosystems Inc.
ABgene USA



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.